Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Classic Galactosemia

Interventions

DRUG

AT-007

Treatment with AT-007 given orally

OTHER

Placebo

Placebo given orally

Trial Locations (3)

Rare Disease Research Center, Atlanta

University of Michigan, Ann Arbor

Children's Hospital Colorado, Aurora